[Drug-induced liver damage caused by antirheumatic drugs--antirheumatic therapy in pre-existing liver damage].
In about 1% of patients treated longterm with nonsteroidal antiinflammatory drugs severe liver damage occurs with an increase of transaminases of more than eightfold. Therefore, measurement of the liver enzymes every 4 to 8 weeks is mandatory. When the transaminase values are greater than 60 U/l, the therapy must be discontinued. Methotrexate may also induce an increase of the transaminases, especially within the first 3 months of therapy. Severe hepatotoxicity, however, rarely occurs. Therefore, transient increases up to 60 U/l may be tolerable, but persistent transaminases higher than 60 U/l require termination of methotrexate therapy.
Breithaupt
H
H
Medizinische Klinik der Justus-Liebig-Universität Giessen.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008111:Liver Function Tests; D008657:Metabolic Clearance Rate / Q000502:physiology; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal
Medikamentöse Leberschäden durch Antirheumatika--Antirheumatische Therapie bei vorbestehenden Leberschäden.